Cathleen Park
Hematology & Oncology · Orange, CANPI 1700319043
Payments from drug & device makers
Across 41 payments — averaging $7750.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$177K
- Mirati Therapeutics, Inc.$96K
- Pfizer$41K
- Immunitybio, Inc.$3K
- Johnson & Johnson$1K
- Daiichi Sankyo Inc.$238
- plus $683 from 5 others
What the payments were for
- Consulting fees$2,40037%
- Speaking & faculty fees$2,50039%
- Food & beverage$1,56924%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 13 | $176,807 |
| Mirati Therapeutics, Inc. | 2 | $95,690 |
| Pfizer | 9 | $40,597 |
| Immunitybio, Inc. | 1 | $2,500 |
| Johnson & Johnson | 3 | $1,243 |
| Daiichi Sankyo Inc. | 4 | $238 |
| Janssen Scientific Affairs, LLC | 4 | $227 |
| AstraZeneca | 2 | $186 |
| Bristol Myers Squibb | 1 | $125 |
| Beigene USA, Inc. | 1 | $122 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$317,759 in reported general payments places this provider in the 80th percentile of 1,363 hematology & oncology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 11 | $164,319 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $186 | $164,31911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Orange
- Nataliya MarOrange$10.4M
- Deepa JeyakumarOrange$10.4M
- Arash Rezazadeh KalebastyOrange$8.7M
- Misako NagasakaOrange$7.4M
- Sai Hong OuOrange$6.8M
- Catherine CoombsOrange$4.9M
- Ritesh ParajuliOrange$3.7M
- Alain AlgaziSan Francisco$119.2M
- David BerzLos Angeles$43.3M
- Jonathan GoldmanSanta Monica$35.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.